CTC Bio씨티씨바이오
060590 · KOSDAQ · ₩060590 · 씨티씨바이오
₩2,585▼ ₩50 (1.90%)End-of-day · Oct 30, 2026 · End-of-day prices.
Income statement
| 2025 | 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|---|
| Revenue | ₩124B | ₩144B | ₩138B | ₩165B | ₩140B |
| Cost of sales | ₩73B | ₩91B | ₩95B | ₩110B | ₩107B |
| Gross profit | ₩50B | ₩53B | ₩43B | ₩55B | ₩33B |
| Operating income | ₩6.2B | −₩4B | −₩4.6B | ₩12B | −₩2.9B |
| Net income | ₩3.2B | −₩5.2B | −₩16B | ₩6B | −₩8B |
| Net income to shareholders | ₩3.2B | −₩5.2B | −₩16B | ₩6.8B | −₩7.3B |
Balance sheet
| 2025 | 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|---|
| Total assets | ₩143B | ₩154B | ₩166B | ₩188B | ₩168B |
| Current assets | ₩69B | ₩74B | ₩84B | ₩90B | ₩71B |
| Cash and equivalents | ₩17B | ₩19B | ₩25B | ₩24B | ₩7.4B |
| Total liabilities | ₩71B | ₩84B | ₩90B | ₩92B | ₩83B |
| Current liabilities | ₩50B | ₩66B | ₩74B | ₩75B | ₩60B |
| Borrowings | ₩27B | ₩28B | ₩31B | ₩34B | ₩35B |
| Total equity | ₩73B | ₩70B | ₩75B | ₩96B | ₩85B |
| Shareholders' equity | ₩73B | ₩70B | ₩75B | ₩96B | ₩85B |
Cash flow
| 2025 | 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|---|
| Cash from operations | ₩4.4B | ₩4.5B | ₩8.2B | ₩18B | ₩6.5B |
| Capital spending | ₩787M | ₩2.1B | ₩1.9B | ₩3.2B | ₩1.7B |
| Free cash flow | ₩3.6B | ₩2.4B | ₩6.3B | ₩15B | ₩4.8B |
Consolidated where available. Amounts in won.
Also known as: CTC Bio / 씨티씨바이오 / 060590 / KRX:060590
Source: KRX statistical information